Literature DB >> 20806969

Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer.

Ping Zheng1, Yong-Xia Liu, Lin Chen, Xun-Hua Liu, Zheng-Quan Xiao, Liang Zhao, Guang-Qiu Li, Jun Zhou, Yan-Qing Ding, Jian-Ming Li.   

Abstract

To better understand the role of PRL-3 in progression and metastasis of colorectal cancer (CRC), we searched for PRL-3 associated proteins using proteomic methods. We identified 39 PRL-3 associated proteins based on proteomic strategy. Stathmin, a key oncoprotein, was proved to be a new PRL-3 associated protein. Notably, co-immunoprecipitation assays in both endogenous CRC cell lines and CRC tissues indicated that PRL-3 could interact with stathmin. And, both stathmin and PRL-3 contributed to microtubule (MT) destabilization of CRC cells. Moreover, gain-of-function and loss-of-function analyses revealed that stathmin promoted proliferation, cell adhesion, and migration of human CRC cells. Immunohistochemical analysis of 149 colorectal tumor samples showed that overexpression of stathmin was strongly correlated with tumor differentiation (P = 0.035), tumor invasion (P = 0.024), lymph node status (P < 0.001), Dukes classification (P < 0.001), and TNM staging (P < 0.001) of CRC patients. Univariate and multivariate survival analyses further supported that overexpression of stathmin protein was a potential independent poor prognostic factor for CRC. Our results reveal many PRL-3 associated proteins for the first time. The oncoprotein stathmin plays a key role in CRC as a new target of PRL-3. Interaction between PRL-3 and stathmin leads to MT destabilization of CRC cells, which contributes to progression and metastasis of CRC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806969     DOI: 10.1021/pr100712t

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  26 in total

1.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

2.  Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer.

Authors:  Wei Nie; Mi-die Xu; Lu Gan; Hai Huang; Qingyu Xiu; Bing Li
Journal:  Lab Invest       Date:  2014-11-10       Impact factor: 5.662

3.  miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer.

Authors:  Feng Guo; Yang Luo; Yi-Fei Mu; Shao-Lan Qin; Yang Qi; Yi-Er Qiu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.

Authors:  Gang Ning; Jonathan G Bijron; Yusuke Yamamoto; Xia Wang; Brooke E Howitt; Michael Herfs; Eric Yang; Yue Hong; Maxence Cornille; Lingyan Wu; Suchanan Hanamornroongruang; Frank D McKeon; Christopher P Crum; Wa Xian
Journal:  J Pathol       Date:  2014-09-30       Impact factor: 7.996

5.  Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Jian Li; Guohuang Hu; Fujiao Kong; Kemin Wu; Kun Song; Jianfeng He; Weijia Sun
Journal:  Pathol Oncol Res       Date:  2015-03-20       Impact factor: 3.201

6.  Stathmin 1 promotes the proliferation and malignant transformation of pancreatic intraductal papillary mucinous neoplasms.

Authors:  Akira Watanabe; Kenichiro Araki; Takehiko Yokobori; Bolag Altan; Norihiro Ishii; Mariko Tsukagoshi; Norio Kubo; Fumiyoshi Saito; Hideki Suzuki; Hiroyuki Kuwano
Journal:  Oncol Lett       Date:  2017-01-17       Impact factor: 2.967

7.  Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma.

Authors:  Han-Ping Hsu; Chien-Feng Li; Sung-Wei Lee; Wen-Ren Wu; Tzu-Ju Chen; Kwang-Yu Chang; Shih-Shin Liang; Chia-Jung Tsai; Yow-Ling Shiue
Journal:  Tumour Biol       Date:  2013-11-12

8.  High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.

Authors:  Koji Harada; Tarannum Ferdous; Toyoko Harada; Yoshiya Ueyama
Journal:  Clin Exp Med       Date:  2015-11-21       Impact factor: 3.984

Review 9.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

10.  A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.

Authors:  Yong Wu; Min Tang; Yuan Wu; Xinxian Weng; Lifang Yang; Wen Xu; Wie Yi; Jinghe Gao; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cell Oncol (Dordr)       Date:  2013-12-05       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.